Novartis Ag

Vicuron Pharmaceuticals Inc.

Vicuron Holdings LLC

Novartis Pharma Gmbh

Simon Bushell

Matthew J LaMarche

Lewis Whitehead

Rakesh K Jain

Mohindra Seepersaud

Lei Shu

Zhengyu Yuan

Charles Francavilla

Arathi Sundaram

Jennifer A Leeds

Kathryn Rene Bracken

Karl Dean

Kwangho Lee

Michael A Patane

Jennifer Leeds

Arathia Sundaram

The present application describes organic compounds of Formula (I) and pharmaceutical compositions thereof, and their use for the treatment, prevention and/or amelioration of diseases, particularly bacterial infections.

Aminothiazoles and their uses

The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases particularly bacterial infections.

Novel N-formyl hydroxylamine compounds of formula I: wherein

N-formyl hydroxylamines compounds

Organic compounds that are useful for the treatment, prevention and/or amelioration of diseases are described.

EFTU inhibitors or aminothiazoles and their uses

Novel N-formyl hydroxylamine compounds and their derivatives are disclosed. These N-formyl hydroxylamine compounds inhibit peptidyl deformylase (PDF), an enzyme present in prokaryotes. The compounds are useful as antimicrobials and antibiotics. The compounds of the invention display selective inhibition of peptidyl deformylase versus other metalloproteinases such as MMPs. Methods of preparation and use of the compounds are also disclosed.

N-formyl hydroxylamines

Growing community of inventors

Boston, MA, United States of America

Simon Bushell